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Neurodegenerative diseases including Alzheimer (AD) and Parkinson (PD) have attracted
attention in last decades due to their high incidence worldwide. The etiology of these
diseases is still unclear; however the role of the environment as a putative risk factor has
gained importance. More worryingly is the evidence that pre- and post-natal exposures
to environmental factors predispose to the onset of neurodegenerative diseases in later
life. Neurotoxic metals such as lead, mercury, aluminum, cadmium and arsenic, as well
as some pesticides and metal-based nanoparticles have been involved in AD due to
their ability to increase beta-amyloid (Aβ) peptide and the phosphorylation of Tau protein
(P-Tau), causing senile/amyloid plaques and neurofibrillary tangles (NFTs) characteristic
of AD. The exposure to lead, manganese, solvents and some pesticides has been related
to hallmarks of PD such as mitochondrial dysfunction, alterations in metal homeostasis
and aggregation of proteins such as α-synuclein (α-syn), which is a key constituent
of Lewy bodies (LB), a crucial factor in PD pathogenesis. Common mechanisms of
environmental pollutants to increase Aβ, P-Tau, α-syn and neuronal death have been
reported, including the oxidative stress mainly involved in the increase of Aβ and α-syn,
and the reduced activity/protein levels of Aβ degrading enzyme (IDE)s such as neprilysin
or insulin IDE. In addition, epigenetic mechanisms by maternal nutrient supplementation
and exposure to heavy metals and pesticides have been proposed to lead phenotypic
diversity and susceptibility to neurodegenerative diseases. This review discusses data
from epidemiological and experimental studies about the role of environmental factors in
the development of idiopathic AD and PD, and their mechanisms of action.
Keywords: Alzheimer’s diseases, Parkinson’s disease, neurodegenerative disorders, beta-amyloid, tau protein,
alpha-synuclein, metals, pesticides
Abbreviations: Aβ, amyloid beta peptide; AICD, amyloid intracellular domain; AD, Alzheimer’s disease; Al, aluminum;
AGE, advanced glycation end products; ApoE, apolipoprotein E; APP, amyloid precursor protein; As, arsenic; α-syn,
alpha-synuclein; BACE1, beta-site APP cleaving enzyme 1; Cd, cadmium; CSF, cerebrospinal fluid; EOAD, early-onset
Alzheimer’ disease; Hg, mercury; HR, hazard ratio; IDE, insulin-like degrading enzyme; LB, Lewy bodies; LOAD, late-onset
Alzheimer’ disease; LRP1, low density lipoprotein receptor-related protein 1; Me-Hg, methyl mercury; Mn, manganese;
MTs, microtubules; NEP, neprilysin; NFTs, neurofibrillary tangles; NPs, nanoparticles; OP, organophosphates; OCl,
organochlorines; PHFs, paired helical filaments; Pb, lead; PD, Parkinson’s disease; PQ, paraquat; PS, presenilin; ROS, reactive
oxygen species; RR, relative risk; sAPPβ, soluble APP beta; SNpc, substantia nigra pars compacta; SNpr, substantia nigra pars
reticulate; Tau, tau protein; P-Tau, phosphorylated Tau; TCE, trichloroethylene; Zn, zinc.
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Introduction
Life expectancy has increased in last decades and health
care improvements have contributed to people living longer.
However, this has also contributed to increase the number of
people with chronic disabling diseases such as Alzheimer (AD)
and Parkinson (PD). Genesis of both neurodegenerative diseases
has not been elucidated and several endogenous (genetic) and
exogenous (environment) factors contribute to the onset and/or
development of these illnesses, which highlights the necessity to
expand the research on identifying the environmental risk factors
that predispose to the development of these neurodegenerative
diseases.
It is known that the etiology of neurodegenerative diseases
is multifactorial, and there is evidence that potential external
factors including lifestyle and chemical exposures are linked with
the risk of the onset of these diseases. Since the vast majority
of AD and PD cases are observed in elderly populations, yet
the exposure to risk factors occurred years or decades before
the diagnosis, the assessment of chronic exposures is difficult
to perform in retrospective studies to associate them with the
onset/development of the disease. Therefore more research for
better definition of exposure, as well as for the identification
of early specific biomarkers for the diagnosis of these diseases
is needed. Attention is now focused on environmental factors
that potentially damage the developing nervous system through
epigenetic mechanisms, resulting in neurodegenerative diseases
later in life. In this review we briefly examined the evidence of
environmental etiologies related to two of the most common
neurodegenerative diseases, AD and PD, from epidemiological
as well as experimental studies.
Alzheimer’s Disease
Alzheimer’s disease is the major form of dementia in elderly
and possibly contributes to 60–70% of cases. It is a progressive,
disabling and irreversible disease (Goedert and Spillantini, 2006).
There are two recognized forms of AD. The first one is named
familial or of early onset (EOAD), which is directly related to
specific gene mutations in the amyloid precursor protein (APP)
and presenilin (PSEN) 1 and 2 genes, both related to the amyloid-
beta (Aβ) peptide synthesis (Piaceri et al., 2013). The EOAD
begins at early age, less than 65 years, and only explains 5% of
all cases. The second one, the late-onset or sporadic AD (LOAD)
is the most common form of AD with 95% of all cases. This form
of AD is not caused by punctual mutations, but some genetic risk
factors have also been described such as polymorphisms in ApoE
(encoding for apolipoprotein E), SORL1 (encoding for neuronal
receptor of ApoE), and GSK3 (encoding for glycogen synthase
kinase 3 beta) genes. The ApoE gene is the strongest genetic
risk factor for LOAD, although it is not sufficient to explain the
occurrence of the disease (Godfrey et al., 2003). Therefore, the
etiology of LOAD remains unclear, and it is suggested that it has
a multifactorial etiology.
Two hypotheses have been most studied for AD development.
One is related to the overproduction of the Aβ peptide.
According to this, neurofibrillary tangles (NFTs) result from
the onset of amyloid deposits as Aβ plaques. While the second
hypothesis suggests that the hyperphosphorylation of the Tau
protein and its subsequent deposition as NFTs is the ultimate
responsible for the disease. The amyloid cascade hypothesis
establishes that Aβ aggregation initiates the brain damage
leading to memory loss and to AD (Hardy and Higgins,
1992). Aβ is normally produced during aging, mediated by
the proteolytic processing of the APP by the amyloidogenic
enzymatic pathway. In this pathway, APP is processed by β- and
γ-secretase complexes producing Aβ, soluble APPβ (sAPPβ) and
the amyloid intracellular domain (AICD). Alternatively, APP can
be processed by the non-amyloidogenic pathway leading to the
production of AICD, sAPPα but not Aβ (Thinakaran and Koo,
2008). Thus Aβ increased levels in the brain of LOAD patients
could be mediated by: (i) an increase in APP expression; (ii)
an increase in the amyloidogenic pathway; or (iii) a reduction
in the non-amyloidogenic pathway. It is stablished that the
increase of a member of the β secretase complex, BACE1 (beta-
site APP cleaving enzyme 1) produces high brain Aβ levels (Sun
et al., 2012). On the other hand, the reduction on the activity
of ADAM10 (a desintegrin and metalloproteinase domain-
containing protein 10) could also lead to the overproduction of
Aβ (Kojro and Fahrenholz, 2005). Furthermore, some mutations
such as those in PSEN 1 or 2, a catalytic member of the
γ-secretase complex, can also increase the production of Aβ
(Piaceri et al., 2013).
Another mechanism to increase brain Aβ levels is through a
reduction in the Aβ degradation. There are proteins collectively
known as Aβ-degrading enzyme (IDE)s that have the ability to
degrade Aβ, including insulin-like IDE, angiotensin-converting
enzyme (ACE), endothelin-converting enzyme (ECE), plasmin,
cathepsin B, aminopeptidase A, matrix metalloproteinase
(MMP) 2 and 9, neprilysin (NEP, neutral endopeptidase) and
others. These enzymes have been suggested as viable therapeutic
targets for AD treatment (Nalivaeva et al., 2012). Finally, a
reduced brain clearance of Aβ can be another pathway for the
brain accumulation of Aβ. Some cholesterol transporters such as
the low density lipoprotein receptor-related protein 1 (LRP1) are
involved in the Aβ export from the brain to the cerebrospinal
fluid (CSF). This receptor links the imbalance of cholesterol
homeostasis with AD pathogenesis (Zlokovic et al., 2010).
On the other hand, aggregates of the microtubule
(MT)-associated protein Tau observed in cell bodies and
apical dendrites as NFTs cause neurofibrillary lesions associated
with AD. Tau is a phosphoprotein mainly localized in the axon of
neurons for the stabilization of MTs; it contains a high number
of serine and threonine residues, and is therefore a substrate of
many kinases (Goedert et al., 1988). The abnormal aggregation
of Tau into insoluble paired helical filaments (PHFs), which
are the major component of NFTs found in cell bodies and
apical dendrites of neurons are lesions associated with AD
(Friedhoff et al., 2000). Under pathological conditions, Tau is
hyperphosphorylated at ‘‘pathological’’ sites leading to MTs
depolymerization, axonal transport disruption and aggregation
(Götz, 2001). It has been proposed that repeat domains (RD) of
the MT-binding domain (MBD) in the C-terminal structure of
Tau can rapidly form PHFs compared with the complete protein,
suggesting that RDs are indispensable for its aggregation (Wille
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et al., 1992), and for Tau filament formation (Tokimasa et al.,
2005).
There is no cure for AD, and therapeutic treatments are
basically to ameliorate the symptoms. Therefore, an early and
opportune diagnosis is indispensable to slow the progression
of the disease. Currently, the determination of Tau and Aβ
levels in blood and CSF are broadly used for the diagnosis
of AD, and several medical tools are also used to confirm
the diagnosis including the medical history, mental status
tests, and evaluations of the brain structure and function with
neuroimaging techniques (Lewczuk et al., 2014). However, these
biomarkers are not sensitive nor specific for AD. Interestingly, an
emerging body of evidence suggests that micro RNAs (miRNAs,
small non-coding RNAs involved in the post-transcriptional
regulation of gene expression) could be putative biomarkers for
detecting neurodegeneration Thus, recent reviews have shown
that some miRNAs are differentially associated with AD by
modulating the expression of important genes involved in Aβ
production (e.g., BACE1) or inflammation (Goodall et al., 2013;
Van den Hove et al., 2014).
FIGURE 1 | Environmental factors associated with Alzheimer’s disease
(AD) development through different mechanisms. Several factors including
metals, pesticides, nanoparticles, and diet can affect the two targets of AD such
as Aβ generation and Tau phosphorylation. The figure depicts the molecular
targets than can be modified at different levels following the
amyloid hypothesis that ends in Aβ senile plaques formation (upper part)
or the hyperphosphorylation of Tau protein and its subsequent deposition
as neurofibrillary tangles (NFTs) (lower part). For more detail see the text.
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Aβ Homeostasis as a Target of Environmental Factors
Environmental factors such as diet (fat-rich), heavy metals,
biogenic metals and pesticides have been involved in AD
development due to their ability to disrupt metabolic pathways
involved in the homeostasis of Aβ. In addition, factors such as
lifestyle (antioxidants and exercise) can prevent AD development
(Figure 1). Many of these environmental factors are oxidative
agents acting through different mechanisms as discussed later.
The brain is particularly vulnerable to oxidative stress do to its
high glucose-based metabolic rate, low levels of antioxidants,
high levels of polyunsaturated fatty acids, and high enzymatic
activities related to transition metals that catalyze the formation
of free radicals (Halliwell et al., 1992). In addition, micromolar
concentrations of Aβ induce the formation of H2O2 in
culture cells leading to neurotoxicity, and the presence of
some antioxidant enzymes prevents the toxicity of the peptide
(Butterfield et al., 2001). The mechanism by which Aβ generates
free radicals is not known, and other endogenous factors also
generate reactive oxygen species (ROS) in AD. For instance,
the ion Fe3+, which is at high concentrations in NFTs and Aβ-
aggregates, catalyzes the formation of reactive species such as
H2O2, as well as advanced glycation end products (AGE) that are
related to neurodegeneration (Smith et al., 1997b). On the other
hand, activated microglia that surrounds the senile plaques is a
source of NO and O2 (Cras et al., 1990), which can react to form
the peroxinitrite radical (ONOO-) (Smith et al., 1997a). Likewise,
inflammation has gained importance in AD pathogenesis (Tuppo
and Arias, 2005). The central nervous system is considered a
privileged site with its own immune system and microglia and
astrocytes are the principal cells involved in the inflammatory
response. It is accepted the microglial chemotaxis of Aβ and the
phagocytosis of amyloid fibrils, effects that produce an increase
in the secretion of pro-inflammatory cytokines and ROS, which
in consequence produces neuronal loss (Rogers and Lue, 2001).
In agreement, astrocytes are also recruited into amyloid plaques
for Aβ degradation (Wyss-Coray et al., 2003), and it is possible
that the activation of microglia and astrocytes is a consequence
of Aβ aggregation. The role of inflammatory processes in AD is
supported by the use of non-steroidal anti-inflammatory drugs
(NSAIDs) to reduce the Aβ levels (Weggen et al., 2001), and the
risk of AD (Etminan et al., 2003).
Metals
Lead (Pb) is a heavy metal well known by its neurological toxic
effects, although a direct association with AD development has
not been reported. Pb affects cognitive abilities, intelligence,
memory, speed processing and motor functions in children
(Mason et al., 2014), while studies in elderly are limited. A cohort
study reported that bone Pb levels were associated with poor
cognitive performance scores in old workers, suggesting that
past Pb exposure can contribute to late cognitive deterioration
(Dorsey et al., 2006). However, a recent study reported no
association between serum Pb levels and AD (Park et al., 2014).
Despite the few epidemiological studies relating Pb exposure
with AD, the evidence is more solid in experimental studies.
The influence of Pb in AD was initially suggested from results
in rats early exposed (from postnatal day 1–20) or late exposed
(at 18–20 months of age) to Pb (200 ppm, drinking water).
Results showed an increase in the APP mRNA expression late in
life after the neonatal exposure, but not in rats exposed as adults
(Basha et al., 2005). Similarly, a study performed in non-human
primates (Macaca fascicularis) exposed to Pb (1.5 mg/Kg/day,
from birth to 400 days) showed that monkeys exposed at a
young age had an increased number of amyloid plaques late in
life (at 23 years old) (Wu et al., 2008). The increased Aβ levels
appear to be mediated by an augmented expression of APP and
BACE1 (Wu et al., 2008). These effects were also observed in
differentiated SH-SY5Y cells incubated with Pb (5–100µM/48 h)
and analyzed 6 days later (Bihaqi and Zawia, 2012). Another
study performed in differentiated SH-SY5Y cells showed an
increase in Aβ secretion and APP expression, as well as reduced
expression and protein levels of NEP (an Aβ IDE), suggesting
that Pb can target both the synthesis and degradation of Aβ
(Huang et al., 2011). However, in a recent work conducted in
our laboratory, Pb did not show changes in NEP expression
in differentiated SH-SY5Y cells exposed to 50 µM Pb, but
an increase in APP levels (Chin-Chan et al., 2015). Another
mechanism by which Pb increases Aβ levels is by reducing the
brain Aβ clearance. A recent study showed that acute Pb exposure
(27 mg/Kg, i.p.) to APP transgenic mice (V717F) reduced the
expression of LRP1, resulting in the accumulation of Aβ in the
hippocampus and cortex of treated mice (Gu et al., 2011). Studies
from this group support that Pb can disrupt the brain export of
Aβ leading to its accumulation and plaques formation (Behl et al.,
2009, 2010).
Exposure to Pb during development is a good example of
an environmental contaminant as a risk factor to promote
neurodegenerative diseases such as AD, supporting the
hypothesis that many adult diseases have a fetal origin (FeBAD)
(Basha et al., 2005). The group of Zawia has extensively
worked on latent responses to prenatal and early postnatal
exposures to Pb. Authors exposed male neonatal rats to Pb
(200 ppm, drinking water) from postnatal day 1–20, or to aging
animals (18–20 months of age), and observed an increase in
the APP mRNA expression as well as in the activity of the
transcription factor Sp1 (one of the regulators of APP) in
the cortex of neonates, and after 20 months of Pb exposure
had ceased. They observed a concomitant increase in Aβ
levels in old animals exposed to Pb at birth. Interestingly,
APP and Aβ protein levels did not respond to Pb exposure
at old age (Basha et al., 2005). Similarly, a study conducted
in cynomolgus monkeys exposed to Pb (1.5 mg/Kg/day, via
infant formula) from birth to 400 days of age, and terminated
23 years later showed increased mRNA levels of APP and Sp1
in the frontal cortex compared with control animals, and high
levels of the biomarker of oxidative DNA damage, 8-oxo-dG,
suggesting an oxidative mechanism (Wu et al., 2008). Aβ1–42
and Aβ-1–40 levels in aged monkeys were also increased,
as well as the intracellular Aβ staining and dense-plaques
compared with age-matched controls (Wu et al., 2008). In
addition, a study reported that gestational exposure to Pb
(0.1, 0.5 and 1%, drinking water) in mice led to increased
brain levels of Aβ and worst spatial memory performance, as
well as increased levels of pro-inflammatory agents such as
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interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-α;
Li et al., 2014a).
Mercury (Hg) is a heavy metal with a high potential to cause
neurotoxicity. Early studies about Minamata and Iraq disasters
led us to understand the neurotoxicity of this metal. It is widely
accepted that Hg disrupts the brain development and produces
cognitive and motor disabilities (Johansson et al., 2007), and
in adults, Hg exposure produces memory loss and cognitive
alterations (Wojcik et al., 2006; Chang et al., 2008). An early
study suggested a link between Hg exposure and AD. Authors
reported increased levels of Hg (in microsomes) and bromide (in
the whole brain), and reduced levels of rubidium (in the whole
brain, microsomes, and nuclei), selenium (Se; in microsomes)
and zinc (Zn; in nuclei) in AD brains compared with controls
(Wenstrup et al., 1990). A subsequent work reported more than
a 2-fold increase in blood Hg levels in AD patients (n = 33)
compared with a control group (n = 65), as well as a positive
correlation between blood Hg concentration and CSF levels of
Aβ (n = 15, Pearson’s correlation r = 0.7440, p = 0.0015) (Hock
et al., 1998). More recently, several metals, including manganese
(Mn), nickel, cadmium (Cd), Pb and Hg were determined in
plasma and CSF of AD patients (n = 173) and healthy controls
(n = 54), however only plasma Mn and Hg concentrations were
significantly higher in AD patients (Gerhardsson et al., 2008).
On the other hand, ApoE4 is a risk factor for AD, probably
because this protein does not have sulfhydryl (SH) groups to
scavenge heavy metals like Hg, whereas ApoE2 has four SH
groups and then the ability to reduce the metal toxicity in the
brain (Mutter et al., 2004). Therefore, ApoEε2 is considered
a protective genotype for AD development (Suri et al., 2013).
Similarly, Godfrey et al. (2003) observed a shift toward the
risky ApoEε4 allele in patients with presumptive Hg-related
neuropsychiatric symptoms with an elevated Hg body burden (n
= 400; Godfrey et al., 2003).
The ability of Hg to increase Aβ levels has been studied
in vitro and in vivo, and the suggested mechanisms include
an increased production, a reduced degradation and/or a
diminished brain clearance of the peptide. Olivieri et al.
(2000) reported an increased secretion of both Aβ-40 and
Aβ-42 when neuroblastoma cells were exposed to 50 µg/dL of
inorganic Hg concomitant with ROS overproduction (Olivieri
et al., 2000), and a study conducted in aggregating brain-cell
cultures of fetal rat telencephalon showed that MeHg (non-
cytotoxic concentrations/10–50 days) produced increased APP
levels accompanied by ROS production and glia activation
(Monnet-Tschudi et al., 2006). Rat pheochromocytoma (PC12)
cells exposed to both inorganic and organic (MeHg) Hg
(10–1000 nM) also showed a dose-dependent overproduction
of Aβ-40 probably by an increase in APP levels as well as
to a reduction in Aβ degradation by NEP (Song and Choi,
2013). However, an increase in Aβ-42 levels was observed
in differentiated SH-SY5Y cells exposed to Hg (10 and 20
µM) but not in the APP expression, and rather a reduced
activity of the Aβ-degrading enzyme, NEP was observed
(Chin-Chan et al., 2015). Negative effects of Hg on Aβ
aggregation have also been published, for example, Atwood
et al. (1998) studied the role of the pH and the ability of
various metals to aggregate Aβ; Zn, Cu and Fe showed the
highest potential on Aβ aggregation, and Hg did not show
an important effect (Atwood et al., 1998). Regarding in vivo
studies, oral administration of 20–2000 µg/Kg/day/4 weeks of
MeHg produced a dose-dependent increase in Aβ-42 in the
hippocampus of male rats, but not significant changes in APP
or NEP protein levels (Kim et al., 2014). Interestingly, authors
observed a reduced brain expression of the LRP1 receptor,
which was positively correlated with increased Aβ levels in the
hippocampus and reduced levels in the CSF, suggesting a reduced
clearance of the pathogenic peptide from the brain (Kim et al.,
2014).
Inorganic arsenic (As) is a known neurotoxic metalloid with
adverse effects in both the neurodevelopment and cognitive
function (Tyler and Allan, 2014), although its effects in elderly
have been less studied. There are few papers evaluating the
role of As exposure as a risk factor for AD development.
A study conducted in rural-dwelling adults and elders in Texas,
US (FRONTIER project) reported that long-term exposure
to low As levels (3–15 µg/L As in water) correlated (after
adjustment by confounders, including theApoEε4 presence) with
a poor score of cognitive abilities and memory, which reflects the
earliest manifestations of AD (O’Bryant et al., 2011). Similarly, a
positive correlation was observed between serum As levels and
the cognitive ability in AD patients from Hong Kong (n = 44,
Pearson’s correlation coefficient r = 0.55, p < 0.0001) compared
with matched controls (n = 41), lower serum Zn concentrations
were observed in AD patients as well (Baum et al., 2010). On the
other hand, the study conducted in several European countries
showed a higher prevalence of AD and other dementias in those
countries with As levels in topsoils about 18 ppm such as Italy,
Switzerland, Spain, France, Belgium and Norway, compared with
countries with lower As levels (in the range of 9 ppm), including
Luxemburg, Denmark, Finland, UK and Nertherlands (Dani,
2010). In experimental studies, the administration of inorganic
As (20 mg/L, drinking water during the gestation and early
postnatal life) to mice produced a significant loss of spatial
memory (Ramos-Chávez et al., 2015).
A plausible mechanism for the cognitive and memory
alterations induced by As exposure is by alterating the amyloid
pathway. Zarazúa et al. (2011) reported that cholinergic
SN56.B5.G4 cells incubated with sodium arsenite or the organic
form dimethylarsinic acid (DMA) (5–10 µM/12–24 h) showed
an increase in APP and sAPPβ levels, and consequently an
increase in Aβ only with DMA. Similar effects were observed in
neurons from Tg2576 mice (a murine model that overexpresses
a mutant form of APP most used in AD). They suggest that
DMA-induced effects may be due by an increased Aβ anabolism
(enhanced APP expression), although authors did not discard
an alteration in the Aβ degradation pathway (Zarazúa et al.,
2011). The mechanism by which As causes Aβ overproduction
has not been determined, but As exposure has been associated
with brain inflammatory responses and oxidative stress, which is
in agreement with the inflammatory and oxidative hypotheses of
AD (Gong and O’Bryant, 2010).
Cadmium is another toxic heavy metal associated with
neurological alterations including memory loss and mental
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retardation (Wang and Du, 2013). An early study observed
higher plasma levels of various metals including Cd, aluminum
(Al), As, and Se in AD patients (n = 24) compared with
healthy volunteers (n = 28) (Basun et al., 1991). Also, the liver
from autopsied AD patients (n = 17) had significant higher
Cd levels compared with age- and sex-matched control subjects
(n = 17) (Lui et al., 1990). However, Gerhardsson et al. (2008)
did not observe significant differences in Cd concentrations in
plasma or CSF in patients with AD (n = 173) compared with
healthy control subjects (n = 54) (Gerhardsson et al., 2008).
There is evidence linking Cd exposure with Aβ overproduction.
Li et al. (2012) observed cognitive alterations accompanied by an
increased production of Aβ-42 and increased size and number
of senile plaques in the cerebral cortex and hippocampus from
APP/PSEN1 transgenic mice treated with Cd (2.5 mg/Kg/4 days,
drinking water). These effects were attributed to a reduced
expression of ADAM10, sAPPα and NEP proteins, suggesting
that the non-amyloidogenic pathway as well as Aβ degradation
are target of Cd exposure (Li et al., 2012). Additionally, authors
reported an increase in free-Zn levels, suggesting that Cd
displaces Zn from its native enzymes, including NEP.
Recently, Ashok et al. (2015) investigated the role of the
exposure to individual metals (As, Pb and Cd) and their
combination in the AD-amyloid pathway in male rats exposed
from gestational day 5 to postnatal day 80 through drinking
water. They reported that metals activated the synthesis of Aβ in
the frontal cortex and/or hippocampus, mediated by an increase
in APP, and in APP-processing enzymes such as beta secretases
BACE1 and PSEN at postnatal days 24 (post-weaning) and
90 (adulthood). Pb was the most potent metal to induce Aβ,
followed by Cd, and As had the smallest effect, however all did
increase the APP production. Interestingly, they demonstrated
a synergic effect of metals mainly due to As, the exposure
to these three cations produced a dramatic increase in Aβ,
PSEN1, BACE1 andAPP, suggesting an enhanced amyloidogenic
processing (Ashok et al., 2015). Authors also observed (Ashok
et al., 2015) increased levels of malondialdehyde (MDA), reduced
activity of antioxidant enzymes, and the induction of 1L-1α and
IL-1β in the frontal cortex and hippocampus of rats exposed to
As + Pb + Cd mixture. Authors suggest that ROS-induced IL-1
overproduction was responsible for the APP expression. This is
supported by the fact that the 5’ÚTR region of the mRNA of APP
has a responsive element for IL-1 (Rogers et al., 1999; Ashok et al.,
2015).
Aluminum is a neurotoxic element involved in the etiology
of neurodegenerative disorders such as AD; however, there is no
consistent evidence. The incident of Al pollution in Cornwall,
UK (1998) gave evidence of Al potential neurotoxicity. Similar
brain pathological characteristic found in AD patients were
observed in subjects exposed to Al in this region (Exley and
Esiri, 2006), as well as alterations in brain functions (Altmann
et al., 1999). A recent study conducted in China reported a
marginal positive association between Al levels in soil and
the mortality caused by AD (Shen et al., 2014); while other
studies reported no association. Experimental evidence appears
to be more consistent. Chronic oral Al administration in rats
(20 g/day in the food/twice weekly from 6 months of age
to the end of their lives) increases the Aβ production by
raising the levels of APP in hippocampal and cortical tissues
(brain regions important for the memory process) (Walton
and Wang, 2009). Cultured rat cortical neurons exposed to Al
(50 µM/48 days) showed an accumulation of Aβ; furthermore,
Al induced conformational changes in Aβ and enhanced
its aggregation forming fibrillar deposits on the surface of
cultured neurons. The aggregated Aβ was dissolved by the
addition of desferroxamine, a chelator of Al (Exley et al.,
1993; Kawahara et al., 2001). The administration of Al plus D-
galactose (an animal model for AD) produced the impairment
of memory and increased the production of Aβ in the cortex
and hippocampus. Additionally, an augmented expression of
BACE1 and a reduction of NEP were observed in this co-
treatment (Luo et al., 2009). Another study showed that Al
reduced the Aβ degradation by decreasing the activity of
cathepsin B, suggesting the activation of the amyloidogenic
pathway and a reduction of the catabolism of Aβ (Sakamoto
et al., 2006). In addition, a reduced expression of LRP1 was also
observed in these mice administered with Al plus D-galactose,
indicating a possible reduction of the clearance of Aβ as well
(Luo et al., 2009). Transgenic mice (Tg2576) fed with Al
(2 mg/Kg, in the diet/9 months) showed an increased production
of Aβ and proteins involved in its anabolism; the accumulation of
amyloid plaques were reversed by the treatment with vitamin E,
suggesting the contribution of Al-induced oxidative mechanism
(Praticò et al., 2002).
As mentioned earlier, miRNA can be biomarkers of early
diagnosis of AD, however few studies have reported the
involvement of pollutants in the miRNAs homeostasis (Ray et al.,
2014). Interestingly, Tg2576 mice exposed to Al (2 mg/Kg/9
months, through the diet) showed an increased expression
of miRNAs (e.g., miR146a and miR125b) involved in a pro-
inflammatory response similar to that observed in AD brains
(Bhattacharjee et al., 2014; Zhao et al., 2014), and treatment
of primary human astroglial (HAG) cells with 100 nM of
Al + Fe increased the expression of NFκB-induced miR-
125b and miR-146a (Pogue et al., 2011); these miRNAs are
reported in AD pathology (Lukiw, 2012). Further studies are
necessary to look for a possible relation between xenobiotic
exposures and the deregulation of miRNA expression involved
in neurodegeneration.
Pesticides
The association between chronic pesticide exposure and the
prevalence of dementias, including AD has not been as well
studied as with other environmental risk factors, and results are
often inconsistent. This is mainly because the difficulty on getting
adequate data on the levels of exposure of individual pesticides,
which is often indirectly evaluated by structure questionnaires
(exposure index). Some of the studies with positive associations
include the one performed in the agricultural Cache County,
Utah, US in about 3000 occupationally pesticides-exposed
participants who were followed-up for 3, 7 and 10 years.
The hazard ratio for developing AD was slightly higher for
organophosphate (OP) pesticides exposure (HR = 1.53, 95% CI,
1.05–2.23) than to organochlorines (OCl) (HR = 1.49, 95% CI,
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0.99–2.24), after adjusting for some variables, including ApoE
genotype (Hayden et al., 2010). Similarly, a recent case-control
study observed a 3.8-fold increase in the OCl metabolite
DDE in serum from AD patients (n = 79) compared with
control participants (n = 86); in addition, authors reported
that the highest tertile of DDE levels was associated with an
increased risk for AD development (odds ratio-OR = 4.18,
95% CI, 2.54–5.82), and carriers of an ApoEε4 allele may be
more susceptible (Richardson et al., 2014). Baldi et al. (2003)
evaluated the association between lifelong cumulative exposure
to pesticides and neurodegenerative diseases in a subsample from
a cohort of elderly people (aged 65 years or older) (PAQUID
study) in southwestern France. Authors analyzed 96 incident
cases of AD (71 women and 25 men) in a 5-year follow-up
approach, and observed a significant association between AD
and occupational exposure to pesticides in men with a relative
risk of 2.4 (95% CI, 1.0–5.6) after adjusting by education and
smoking. Results were not significant in women (Baldi et al.,
2003).
The role of pesticides in alterations observed in cognitive
functions and AD has been suggested based on epidemiological
studies, but the mechanisms have been poorly explored. In vitro
studies performed in differentiated SH-SY5Y cells incubated with
OCl pesticides such as DDE and its parent compound DDT
(1 µM/48 h) showed increased APP protein levels, although
authors did not evaluate Aβ levels (Richardson et al., 2014).
A recent study reported that DDT augmented Aβ levels by
increasing APP and BACE1 levels in human neuroglioma
H4-AβPPswe cells, as well as by reducing the clearance and
degradation of the peptide by targeting the Aβ-degrading
enzyme, IDE and the ATP-binding cassette transporter A1
(ABC1; Li et al., 2015). Regarding in vivo data, chlorpyrifos
(CPF), an OP insecticide associated with cognitive impairment,
oxidative stress and neuronal damage caused a significant
increase in Aβ levels in the cortex and hippocampus, as well as
increased memory loss and reduced motor activity in Tg2576
mice 6 months after an acute subcutaneous administration of
50mg/Kg of CPF (Salazar et al., 2011). However, Peris-Sampedro
et al. (2014) did not find increased Aβ levels neither significant
changes in memory acquisition in Tg2576 mice treated with
CPF (25 mg/Kg/twice weekly/4 weeks, intragastric) and analyzed
6 months later (Peris-Sampedro et al., 2014). More studies are
needed to better understand the mechanisms by which OCl, OP
and other insecticides are linked to AD.
Paraquat (PQ), is a common used herbicide that has been
suggested to be involved in AD development. A recent study
showed that treatment of wild type and APP transgenic
(Tg2576) mice with PQ (10 mg/Kg/twice a week/3 weeks)
produced a significant increase in Aβ levels in transgenic mice
that was associated with mitochondrial oxidative damage in
cerebral cortex leading to the impairment of learning and
memory. Interestingly, the overexpression of peroxiredoxin 3,
a mitochondrial antioxidant defense enzyme produced an
improvement in cognitive functions and a significant reduction
in Aβ levels in APP transgenic mice exposed to PQ (Chen
et al., 2012a), suggesting that pro-oxidant xenobiotics like PQ can
contribute to AD.
Nanoparticles
As the synthesis of NPs for different applications, including
drug delivery strategies in the treatment of AD is growing, it is
necessary to study the potential toxic effects on proteins related
to AD development.
There are not epidemiological studies associating the
exposure to NPs with AD. However, there is increasing
experimental evidence suggesting the potential role of NPs in
brain damage. A recent study reported that nasal administration
of TiO2-NPs (2.5–10 mg/Kg/90 days) to mice caused neuronal
death in the hippocampus, oxidative stress and gliosis, and
microarray analysis revealed a decline of genes associated with
memory and cognition (Ze et al., 2014). Similarly, rats exposed
to CuO-NPs (0.5 mg/Kg/day/14 days, i.p.) showed worst spatial
cognition and a reduction in electrophysiological endpoints
such as long-term potentiation, which matched with augmented
levels of ROS and lipid peroxidation products (MDA and
4-hydroxinonenal-HNE), and reduced levels of antioxidants
enzymes (An et al., 2012). Studies of NPs of Al, Cu and Ag
administered at different doses and routes in rats and mice
showed that they produce brain alterations such as motor,
sensory and cognitive deteriorations (Sharma et al., 2009;
Sharma and Sharma, 2012). However a recent study did not
observe memory loss in adult mice administered with Ag-NPs
(10, 25, and 50 mg/Kg/7 days) (Liu et al., 2013). Regarding
in vitro studies, the exposure of human (SK-N-SH) and
mouse (Neuro-2a) neuroblastoma cells to silica NPs (SiNPs)
(10 µg/mL/24 h) raised the intracellular content of Aβ in both
cell lines, which was associated with increased APP and reduced
NEP protein levels. These effects may be mediated by ROS
production, since SiNPs increased the production of intracellular
ROS (Yang et al., 2014). Likewise, treatment of Neuro-2a cells
to silver NPs (AgNPs, 12.5 µg/mL/24 h) showed the deposition
of Aβ plaques and an increased expression of APP, while
NEP and LPR1 (or LDLR) expression and protein levels were
reduced, suggesting that AgNPs can induce AD by altering the
amyloidogenic pathway: Aβ synthesis, degradation or clearance
(Huang et al., 2015). Interestingly, authors also reported an
increased expression of genes involved in the inflammatory
response such as IL-1, C-X-C motif chemokine 13 (CXCL13),
macrophage receptor with collagenous structure (MARCO), and
glutathione synthetase (GSS) (Huang et al., 2015).
Tau Hyperphosphorylation by Environmental Factors
Several environmental factors have shown to mediate AD
development through alterations on Tau phosphorylation and/or
aggregation (Figure 1).
Metals
In vivo and in vitro studies have suggested the potential of Hg
to induce P-Tau. Fujimura et al. (2009) reported an increased
neuronal death and more migrating astrocytes in cerebral cortex
of male mice exposed to MeHg (30 ppm, drinking water), as
well as increased levels of P-Tau mediated by c-jun N-terminal
kinase (JNK; Fujimura et al., 2009). An in vitro study showed
that inorganic Hg (50 µg/dL/30 min) increased P-Tau in
SH-SY5Y cells by a ROS-dependent mechanism, which was
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reverted by the co-treatment with the antioxidant melatonin
(Olivieri et al., 2000). Another study demonstrated that Hg
ions coordinate with Cys291 of the second repeated (R2) of
the MT-binding domain of Tau increasing the heparin-induced
aggregation, and a conformational change in Tau demonstrated
by circular dicroism (CD) analysis (Yang et al., 2010). On the
other hand, Cd appears to play a role in Tau hypothesis since
it promotes the aggregation of this protein. It was shown that
Cd (II) accelerates heparin-induced aggregation of the third
repeated (R3) of Tau. The binding of Cd (II) to the dimeric
R3 produces changes on its conformation demonstrated by
CD (Jiang et al., 2007). Subchronic As administration to rats
(NaAsO2 at 3 and 10 mg/Kg/day/4–12 weeks, intragastric)
induced P-Tau, suggesting that As-destabilization and disruption
of the cytoskeletal framework may lead to axonal degeneration
(Vahidnia et al., 2008). Regarding Pb, it was reported that
infantile Pb exposure in cynomolgus monkeys elevated mRNA
and protein levels of Tau as well as its transcriptional regulators
(Sp1 and Sp3) in aged primates (23 years old). An increase in
P-Tau phosphorylation and mRNA and protein levels of cyclin
dependent kinase 5 (cdk5, a kinase that phosphorylates Tau)
were also observed (Bihaqi and Zawia, 2013). Other studies also
reported that maternal (Li et al., 2010a) and early postnatal
exposures (Liu et al., 2014) to Pb produced significant increased
P-Tau levels and cognitive impairment in mice. Finally, chronic
Al exposure caused Tau aggregation, and it was suggested that
Al is bound to P-Tau in the Al-NFTs lesions (Singer et al.,
1997; Shin et al., 2003). Also, a study showed that Al is able
to confer resistance to the degradation of PHFs both in vivo
and in vitro (Shin et al., 1994), and it can inhibit the activity
of the protein phosphatase 2 (PP2), which is involved in P-Tau
de-phosphorylation (Yamamoto et al., 1990).
Pesticides
There is some evidence suggesting that pesticide exposure
can disrupt Tau function. A recent study showed that the
administration of the insecticides deltamethrin (pyethroid)
and carbofuran (carbamate) to rats (daily administration
by gavage/28 days) produced neuronal death in the cortex
and hippocampus and a dysfunction in the spatial memory
and learning. These alterations were attributed to a reduced
expression of synaptic proteins involved in the memory
consolidation. Additionally, P-Tau and activation of p-GSK3β
(a major kinase that phosphorylates Tau) were observed (Chen
et al., 2012b). Similarly, Wills et al. (2012) showed P-Tau in
the striatum, through the activation of p-GSK3β, as well as
hyperacetylation of α-tubulin inmice treated with PQ (10mg/Kg,
i.p., twice weekly/6 weeks), suggesting a cytoskeleton remodeling
(Wills et al., 2012).
Nanoparticles
The effect of NPs on Tau phosphorylation has not been
extensively studied. Silica NPs (siNPs) used in medicine are also
able to increase P-Tau at Ser262 and Ser396, two phosphorylation
sites characteristic of AD. It was demonstrated that this effect
was dependent on the activation of the kinase GSK3β in human
SK-N-SH and mouse Neuro-2a cells by a mechanism probably
mediated by oxidative stress, since ROS were increased in cells
exposed to these NPs (Yang et al., 2014).
Parkinson’s Disease
Parkinson Disease is a chronic and progressive neurological
disorder characterized by the selective loss of dopaminergic
neurons of the substantia nigra pars compacta (SNpc). The
cardinal features of the syndrome are related to motor
dysfunction including tremor at rest, rigidity, akinesia (or
bradykinesia), and postural instability. The motor symptoms
appear when at least 60% of dopaminergic neurons are lost
and 80–85% of dopamine content in the striatum is depleted
(Jankovic, 2008; Wirdefeldt et al., 2011). Additional to the
neuronal loss, the main neuropathological hallmark of PD is the
presence of Lewy bodies (LB) in the surviving neurons, which
are eosinophilic cytoplasmic inclusions containing aggregates
of protein such as α-synuclein (α-syn) (Gibb and Lees, 1988;
Spillantini et al., 1998). PD is the second most common
neurodegenerative disorder after AD. Due to the lack of
specific/differential diagnostic biomarkers, the diagnosis of
PD is based on clinical criteria of specific cardinal motor
signs of the disease and on the response to levodopa.
PD diagnosis is confirmed by the depletion of brain stem
pigmented neurons and the presence of LB at necropsy, this
is the reason of the misclassification of PD cases (about
10–15%) (Schrag et al., 2002; Jankovic, 2008). There is no
cure for PD, and the existing therapies only provide brief
relief of motor symptoms through improving the dopamine
deficit or by surgical methods. This highlights the need
of research on early specific/differential biomarkers to have
more accurate diagnosis of neurodegenerative disorders, as
well as biomarkers for the identification of populations
at risk to implement neuroprotective therapies (Jankovic,
2008).
As in the case of AD, circulating miRNAs are being studied
as differential biomarkers for PD. Some reviews have recently
addressed this topic, showing the association of specific miRNAs
for some genes involved in PD, such as SNCA and LRRK2
(encoding for leucine–rich repeat kinase 2) with PD development
(Goodall et al., 2013; Maciotta et al., 2013). Some studies
have reported differentially expressed miRNAs in serum of PD
patients not observed in control subjects or in other diseases.
For example, Vallelunga et al. (2014) reported two differentially
expressed miRNAs (miR-30c and miR-148b) in Italian PD
patients (n = 25 vs. 25 healthy controls) (Vallelunga et al., 2014),
and another study found that serum levels of miR-29c, miR-29a,
and miR-19b were down-regulated in PD patients (n = 65 vs.
65 healthy controls) from Barcelona, Spain (Botta-Orfila et al.,
2014). Also, a reduced expression of miR-34b and miR-34c in
several brain areas including the substantia nigra of PD patients
(n = 11 vs. 6 healthy controls) was detected; interestingly the
misregulation of miR-34b/c was observed in patients in pre-
motor stages of the disease. Additionally, these miRNAs were
deregulated in differentiated SH-SY5Y dopaminergic neuronal
cells, which was associated with altered mitochondrial function,
oxidative stress and ATP depletion, as well as decreased protein
levels of DJ1 (a mitochondrial peroxidase) and Parkin (an E3
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ubiquitin ligase) that are associated with the familial form of PD
(Miñones-Moyano et al., 2011).
Although the research on PD has rapidly advanced, the
molecular mechanisms involved are still unclear and its
etiology is complex. Several molecular mechanisms of neuronal
death in PD pathogenesis have been described including
mitochondrial dysfunction, impairment of protein quality
pathways, oxidative/nitrative stress, microglia activation and
inflammation. These mechanisms converge and are consistent
with a major role of oxidative stress in PD, which damage
organelles and proteins leading to increased protein aggregates
(e.g., α-syn), that in turn overwhelms the degradation systems
leading to a self-perpetuating cycle and further oxidative stress
(Wirdefeldt et al., 2011; Goldman, 2014). The evidence in
postmortem PD brains supports these mechanisms, as well as a
decreased in reduced GSH levels, α-syn aggregation, proteasome
impairment and autophagy dysfunction (review in Navarro-
Yepes et al., 2014).
A fraction of PD occurrence has a clear familial inheritance
and it is related to mutations in at least 6 genes that have been
associated with PD onset. The identification of genes such as
SNCA or PARK1 encoding for α-syn (maybe involved in the
regulation of dopamine release and transport), LRRK2 or PARK8
encoding for LRRK2 (or Dardarin), PARK7 encoding for DJ1,
PARK6 or PINK1 encoding for PTEN-induced putative kinase
1 (PINK1, a mitochondrial kinase), and PARK2 encoding for
Parkin have provided clues about the molecular mechanisms
involved in its pathogenesis (Corti et al., 2011; Cookson,
2012). However, 90% of PD cases are sporadic and cannot be
attributed only to genetic factors, which suggests that PD have a
multifactorial etiology (Goldman, 2014). In addition to the aging,
which is the main risk factor for PD (Tanner and Goldman,
1996), epidemiological evidence suggests that the exposure to
environmental toxicants, mainly pesticides, metals and solvents
could increase the risk of developing PD, and factors such
as tobacco consumption can protect against PD development
(Figure 2; Hatcher et al., 2008; Gao and Hong, 2011).
Metals
It has been proposed that chronic exposure to heavy metals
such as iron, Pb and Mn and their combinations can be
associated with an increased risk of developing PD, since they
accumulate in the substantia nigra and generate oxidative stress.
However, epidemiological evidence is controversial (Lai et al.,
2002). The epidemiological evidence of Pb association with PD
is more consistent because the accumulative lifetime exposure
can be estimated through Pb concentration in bone that has
a half–life of years to decades. Initially, Kuhn et al. (1998)
reported that 7 out of 9 postal workers exposed to lead-
sulfate batteries for up to 30 years developed parkinsonian
symptoms, suggesting that Pb intoxication may play a role in
the occurrence of these symptoms (Kuhn et al., 1998). Coon
et al. (2006) evaluated this association in 121 PD patients vs.
414 controls and found that chronic Pb exposure (evaluated
by Pb concentrations in tibial and calcaneal bones) increased
2–fold the risk of PD (OR = 2.27, 95% CI, 1.13–4.55) for
individuals in the highest quartile of lifetime Pb exposure relative
to those in the lowest quartile (Coon et al., 2006). In the
same way, it was reported that the cumulative exposure to
Pb increases the risk of PD (OR = 3.21, 95% CI, 1.17–8.83)
in 330 PD patients (vs. 308 controls) recruited from 4 clinics
for movement disorders in Boston, MA area (Weisskopf et al.,
2010b), and the exposure to Pb for more than 20 years showed a
stronger association with PD risk in a health system population-
based case-control study (144 cases vs. 464 controls) from the
metropolitan Detroit area (Gorell et al., 2004). At the molecular
level, Pb exposure significantly decreases the dopamine release
and the dopamine D1 receptor sensitivity post-synaptically in
microdialysate samples from rats subchronically exposed to Pb
(50 ppm/90 days) (Kala and Jadhav, 1995), and in rats treated
with 250 ppm of Pb for 3–6 weeks through drinking water
(Tavakoli-Nezhad and Pitts, 2005). Furthermore, it increases
the lipid peroxidation and reduces the antioxidant cell capacity
(Sandhir et al., 1994), and causes fibrillation and aggregation
of α-syn (Yamin et al., 2003), which induces hippocampal
injury and decreases the ability of learning and memory in rats
exposed to 0–300 ppm of Pb (Yamin et al., 2003; Zhang et al.,
2012).
Manganese is an essential element with important
physiological functions for cellular homeostasis. The
epidemiologic evidence does not provide sufficient support
for an association betweenMn exposure and PD risk (Wirdefeldt
et al., 2011; Mortimer et al., 2012). Only one case–control
study (144 cases vs. 464 controls) in a population from the
metropolitan Detroit area reported an increase of PD risk
when the exposure to Mn was over 20 years (OR = 10.63, 95%
CI, 1.07–105.99) (Gorell et al., 2004). However, occupational
or environmental exposures to Mn have been associated
with a neurological syndrome that include cognitive deficits,
neuropsychological abnormalities and Parkinsonism (Guilarte,
2013). Mn was related to PD since 1837, when it was noted that
high Mn exposures caused a severe and debilitating disorder
known as ‘‘manganism’’ or manganese–induced Parkinsonism,
which consists on an extra pyramidal syndrome that resembles
the dystonic movements associated with parkinsonian symptoms
(Couper, 1837; Jankovic, 2005), but it is clinically distinct from
PD since patients do not respond to dopamine replacement
therapies (Cook et al., 1974; Huang et al., 1993; Lu et al., 1994).
Several cases of Mn–induced Parkinsonism have been reported
in individuals whose professions involve prolonged contact
with high atmospheric levels of Mn such as welders, miners
and smelters (Rodier, 1955; Wang et al., 1989; Lee, 2000).
Several investigations have shown that sustained exposure
to low-concentrations (below the current US standard of
5.0 mg/m3) is consistent with early manganism, suggesting
that Mn is a neurotoxic chemical (Park, 2013). Patients with
manganism and primates experimentally intoxicated with Mn
consistently show damage to the globus pallidus, which is in
contrast with PD where there is a preferential degeneration
of dopamine neurons in the SNpc and preservation of the
pallidum (Perl and Olanow, 2007). Likewise, it was observed
microglia activation in the substantia nigra pars reticulate
(SNpr) and SNpc in Cynomolgus macaques exposed to Mn
(5–6.7 mg/Kg/week/10 months) (Verina et al., 2011). In vitro,
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FIGURE 2 | Molecular mechanisms altered by environmental
factors related to increased Parkinson’s disease risk. Exposure
to environmental toxicants mainly pesticides, metals and solvents may
lead to the selective loss of dopaminergic neurons on the substantia
nigra pars compacta (SNpc) through the dysregulation/alteration of the
molecular mechanisms implicated on PD development such as
mitochondrial dysfunction, impairment of protein quality pathways,
microglia activation and inflammation, which converge in the production
of oxidative stress as the main factor in PD. For more detail see
the text.
it has been observed that Mn treatment (50–300 µM MnCl2/
3–48 h) induces cytochrome C release and activation of caspases
9 and 3, as well as protein aggregation in N27 dopaminergic
neuronal cells that stably express α-syn (Harischandra et al.,
2015).
Iron is an essential element transported into the brain
through the transferrin receptor and divalent metal transporter
1 (DMT1; Zheng and Monnot, 2012). It has been evaluated
in relation to the risk of PD in few epidemiological studies
without convincing evidence (Rybicki et al., 1993; Logroscino
et al., 2008; Miyake et al., 2011; Abbott et al., 2012). However,
iron and its deregulated homeostasis have been proposed to
have a role in the pathogenesis of PD because of its pro-
oxidants characteristics that may lead to ROS generation via
Fenton and Haber–Weiss reactions (Stohs and Bagchi, 1995;
Sian-Hulsmann et al., 2011). The substantia nigra has the
highest levels of iron in the human brain, probably due to the
presence of neuromelanin in pigmented SNpc dopaminergic
neurons that have an impressive capacity of chelating metals,
iron in particular; however, this may be a dual-edged sword
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that may increase their vulnerability since iron may react with
ROS produced from dopamine metabolism and promote the
further generation of highly toxic radicals (Zecca et al., 2002,
2004). Alterations in iron distribution have been observed
in the substantia nigra of PD postmortem brains (Dexter
et al., 1987, 1991; Hirsch et al., 1991). On the other hand,
it was observed in postmortem samples that although the
total iron concentration in the whole substantia nigra was
not significantly different between parkinsonian and control
samples, there was an increase in the free-iron concentration and
a decrease in iron–binding ferritin levels, ferritin sequestrates
the excess of iron under physiological conditions (Wypijewska
et al., 2010). Likewise, it was reported that free-iron induces
fibrillation and aggregation of α-syn in a dose- and time-
dependent way in SK-N-SH cells incubated with ferric iron
(1–10 mmol/L/24–48 h) (Li et al., 2010b). Mice administered
with iron (120 µg/g of carbonyl iron, oral gavage) at a dose
equivalent to that found in iron-fortified human infant formula
(12 mg/L of iron) from days 10 to 17 post-partum (an equivalent
period to the first human year of life) showed a progressive
midbrain neurodegeneration and enhanced vulnerability to
toxic injury at 12 and 24 months of age (Kaur et al.,
2007).
Pesticides
The hypothesis that pesticide exposures may be related to PD
development was prompted by the discovery that intravenous
injection of 1-methy l-4pheny l-1, 2, 3, 6-tetrahydropyridine
(MPTP), a byproduct of the synthesis of heroin, developed
a Parkinson syndrome clinically indistinguishable from PD
(Langston et al., 1983); subsequent findings showed that MPTP
selectively damaged dopaminergic neurons in the substantia
nigra (Langston and Ballard, 1983; Langston et al., 1984). Since
then, environmental factors with similar toxicological profiles
have received attention as potential risk factors for PD.
A meta-analysis conducted in 2000 evaluated the association
between pesticide exposures and PD in 19 case–control studies
published between 1989 and 1999. Authors showed that most
studies found an elevated risk of PD with the exposure to
pesticides, the calculated combined OR was 1.94 (95% CI,
1.49–2.53); similar ORs were observed in studies conducted in
United States, Asia, Europa and Canada. Additionally, it was
observed that the risk of PD increased with longer exposure
times, with an OR of 5.81 (95% CI, 1.99–16.97) for ≥10
years of exposure; however, specific types of pesticides were
not identified (Priyadarshi et al., 2000). Subsequently, Brown
et al. (2006) reviewed 31 case–control studies published until
2003, and found that about half of them reported significant
associations between pesticide exposure and PD risk with ORs
from 1.6–7. Interestingly, in most studies, authors observed a
positive association between the exposure to herbicides and
insecticides and PD risk, but not with the exposure to fungicides
alone (Brown et al., 2006).
In line with this, a recent review by Freire and Koifman
(2012) analyzed the epidemiological evidence published between
2000 and 2011, including ecological, cross–sectional, prospective
and case–control studies. They found that 7 out of the 8
prospective (cohort) studies provided evidence of an association
between pesticide exposure and PD, reporting risk estimates
of 2-fold or higher. Among 23 case–control studies, 13 studies
reported a significant increased risk of PD for the professional
use of pesticides in comparison with unexposed controls, with
ORs ranging from 1.1 to 1.4, which is in agreement with the
review of Priyadarshi in the 1990’s (Freire and Koifman, 2012).
Furthermore, van der Mark et al. (2012) performed a systematic
review and calculated the summary risk ratio (sRR) from
39 case–control studies, 4 cohort studies and 3 cross–sectional
studies. When a job–exposure matrix was constructed, a higher
sRR (2.5, 95% CI, 1.5–4.1) was observed compared with
self–reported exposure evaluation (1.5, 95% CI, 1.3–1.8). This
meta–analysis found a positive association between PD and
insecticides (sRR = 1.50, 95% CI, 1.07–2.11), and herbicides
(sRR = 1.40, 95% C, 1.08–1.81), but not with fungicides
(sRR = 0.99, 95% CI, 0.71–1.40) (van der Mark et al., 2012),
in agreement with Brown et al. (2006) and Freire and Koifman
(2012). Other factors related to pesticide exposure such as
well–water consumption, farming, and rural living have been
associated with an increased PD risk. The meta–analysis of
Priyadarshi et al. (2001) found a combined OR of 1.56 (95% CI,
1.18–2.07) for rural living, 1.42 (95% CI, 1.05–1.91) for farming
and 1.26 (95% CI, 0.97–1.64) for well–water consumption.
However, whether of these factors are independent risk factors
or correlated with pesticide exposure could not be determined
(Priyadarshi et al., 2001).
In support to epidemiological evidence, increased levels of
some pesticides have been quantified in postmortem brains from
PD patients. High concentrations of some OCl pesticides have
been observed in PD cases compared with controls, including
dieldrin, lindane, and p-p-DDE (Fleming et al., 1994; Corrigan
et al., 1998, 2000). In the same way, 2 epidemiologic studies
reported a significant association (OR ranging from 1.3 to 1.8)
between dieldrin use and PD in farmers participants in the
Agricultural Health Study (AHS; Kamel et al., 2007; Tanner
et al., 2011). Another nested case–control study within the
Finnish Mobile Clinic Health Examination Survey in Finland,
with serum samples collected during 1968–1972, observed that
increasing serum concentrations of dieldrin were associated with
an increased PD risk (OR = 1.95, 95% CI, 1.26–3.02) in 68
cases vs. 183 controls restricted to never smokers, while no
other OCl pesticide showed an association (Weisskopf et al.,
2010a).
The epidemiologic evidence that dieldrin exposure may
be associated with PD is supported by toxicological data at
molecular level. Dieldrin may cross the blood–brain barrier and
remains in lipid-rich tissues such as the brain (Kanthasamy
et al., 2005), and it has been shown that it is selectively
toxic to dopaminergic neurons and could induce several of the
pathologic mechanisms of PD including the depletion of brain
dopamine levels, increased ROS in nigral dopaminergic neurons,
inhibition of mitochondrial oxidative phosphorylation that lead
to a reduction of cellular ATP production, alteration of the
mitochondrial membrane potential and cytochrome C release
in animal models such as rats and mice chronically exposed to
dieldrin (0.3–3 mg/Kg/day in the diet) (Bergen, 1971; Wagner
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and Greene, 1978; Purkerson-Parker et al., 2001; Hatcher et al.,
2007), and in primary mesencephalic cultures or dopaminergic
cell lines (0.01–300 µM) (Sanchez-Ramos et al., 1998; Kitazawa
et al., 2001, 2003; Kanthasamy et al., 2005). Aggregation of
α–syn, ubiquitin–proteasome impairment function (Uversky
et al., 2001; Sun et al., 2005) and microglia activation (Mao and
Liu, 2008) have also been observed.
Paraquat is a quaternary nitrogen herbicide used worldwide.
Due to its structural similarity to MPP (the active metabolite
of MPTP), it was thought to be toxic to dopaminergic neurons
and thus might be related to PD. The possible association
between PQ and PD received attention from the study of Liou
et al. (1997) performed in PD patients (120 patients and 240
controls) in Taiwan, in which the pesticide use was associated
with an increased risk of developing PD, being higher for
those individuals who reported using PQ (Liou et al., 1997).
Likewise, Tanner et al. (2011) reported a significant association
between PD and the use of oxidative pesticides, including PQ
(OR = 2.5, 95% CI, 1.4–4.7) in professional pesticide applicators
(110 cases and 358 controls) (Tanner et al., 2011). Similarly, other
epidemiologic studies have associated the exposure to PQ with
PD (Hertzman et al., 1990; Ascherio et al., 2006; Kamel et al.,
2007; Wang et al., 2011).
Paraquat is taken up into dopaminergic terminals by the
dopamine transport and organic cation transporter 3 (Rappold
et al., 2011), and causes cellular toxicity by oxidative stress
through the cellular redox cycling generating superoxide radical
by the oxidation of NADPH, which in turn impairs the
restauration of GSH levels and thus the activity of several
antioxidant systems (Berry et al., 2010; Franco et al., 2010).
It has been observed that repeated administrations of PQ to adult
mice and rats (5–10 mg/Kg/ week/at least 3 weeks, i.p.) increase
ROS levels in the striatal homogenate, induce a dose-dependent
decrease in dopaminergic neurons from the substantia nigra,
a decline in striatal dopamine nerve terminal density, and a
neurobehavioral syndrome characterized by reduced ambulatory
activity (Brooks et al., 1999; McCormack et al., 2002; Kuter
et al., 2010). PQ also reproduces other biochemical and
neuropathological characteristics of human Parkinsonism such
as microglia activation (Wu et al., 2005; Purisai et al., 2007),
α-syn up-regulation and fibrillation (Uversky et al., 2001;
Manning-Bog et al., 2002), increases lipid peroxidation (increase
of 4-hydroxynonenals) (McCormack et al., 2005), alters parkin
solubility promoting its intracellular aggregation (Wang et al.,
2005), induces a proteasome dysfunction in SH-SY5Y cells (Ding
and Keller, 2001; Yang and Tiffany-Castiglioni, 2007), as well as
in homogenates from postmortem PD brains (McNaught and
Jenner, 2001; McNaught et al., 2002), impairs mitochondrial
function at the level of complex III to generate ROS (Castello
et al., 2007; Drechsel and Patel, 2009), promotes cytochrome C
release (González-Polo et al., 2004; Fei et al., 2008), induces GSH
depletion (Schmuck et al., 2002; Kang et al., 2009), and causes
cell injury leading to apoptotic cell death (Berry et al., 2010;
Franco et al., 2010). PQ has been used as a toxicological model for
PD that has permitted getting important information about the
mechanisms involved in the neurodegeneration associated with
PD (Gao and Hong, 2011).
Rotenone, an OP insecticide has also been associated with
an increased risk of PD. Two epidemiological studies found an
association between rotenone exposure and PD risk, reporting
an increased risk of 10–fold (OR = 10.0, 95% CI, 2.9–34.3) in
East Texas farmers (Dhillon et al., 2008), and 2.5-fold (OR = 2.5,
95% CI, 1.3–4.7) in PD cases (n = 110) compared with controls
(n = 358) from professional pesticide applicators participants in
the AHS (Tanner et al., 2011). Rotenone can freely cross the
blood–brain barrier and is a well-establishedmitochondrial toxin
that specifically inhibits the complex I (NADH–dehydrogenase)
of the electron transport chain leading to ATP depletion,
energy failure and mitochondrial ROS production, which in
turn induces cytochrome C release and apoptotic cell death
(Clayton et al., 2005; Radad et al., 2006; Sherer et al., 2007).
It has been shown that, like MPTP, rotenone treatment in
animal models (1.5–3 mg/Kg/day/up to 3 weeks) reproduces
features of PD such as bradykinesia, postural instability and/or
rigidity, reduces the tyrosine hydroxylase-positive neurons in the
substance nigra, induces a loss of striatal dopamine, and the
accumulation of α-syn and poly-ubiquitin positive aggregates in
remaining dopaminergic neurons (Betarbet et al., 2000; Sherer
et al., 2003; Cannon et al., 2009). Likewise, Betarbet et al.
(2006) observed that chronic administration of 3.0 mg/Kg/day
of rotenone for up to 5 weeks to male rats caused the
oxidation of DJ-1, accumulation of α-syn, and proteasomal
impairment (Betarbet et al., 2006). These effects were also
observed in neuroblastoma SK-N-MC cells treated with rotenone
(5 nM/4 weeks), as well as a loss of GSH, oxidative DNA and
protein damage and caspase-dependent death (Sherer et al.,
2002; Betarbet et al., 2006). Rotenone has also the capacity
to activate microglia (Sherer et al., 2003); Gao et al. (2002)
demonstrated that the addition of microglia to primary neuron-
enriched cultures (neuron/glia cultures) markedly increased
the dopaminergic neurodegeneration induced by rotenone (1
nM/8 days), and this neurotoxicity was attenuated by the
inhibition of NADPH oxidase or scavenging the superoxide
radical that is liberated from the microglia (Gao et al.,
2002). Since rotenone recapitulates several mechanisms of PD
pathogenesis, this pesticide is currently used as a toxicological
model to study the underlying mechanisms on the PD
development.
Despite the widespread use of OP insecticides such as
malathion, methyl parathion, chlorpyriphos and diazinon, not
many studies have evaluated the association between specific
OP and PD risk. Dhillon et al. (2008) found a 2–fold increase
(OR = 2.0, 95% CI, 1.02–3.8) in the risk of PD in Texan
agricultural workers exposed to chlorpyriphos (cases = 100,
controls = 84) (Dhillon et al., 2008). An increased risk of PD
was also observed in rural residents from California possibly
exposed to high levels of chlorpyriphos (OR = 1.87, 95% CI,
1.05–3.31) and diazinon (OR = 1.75, 95% CI, 1.12–2.76) through
the consumption of contaminated well–water (Gatto et al., 2009).
One study conducted in a population from the Group Health
Cooperative (GHC) inWesternWashington State occupationally
exposed to methyl parathion found a high risk of PD (OR = 8.08,
95%CI, 0.92–70.85), although the association was not statistically
significant (Firestone et al., 2005). This is particularly relevant,
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because parkinsonian effects have been reported in cases of
patients intoxicated with OP (Bhatt et al., 1999).
Solvents
Solvents are widespread used due to their commercial
applications, including metal degreasing, dry cleaning, and
as ingredients of paint thinners and detergents. Some solvents
are lipophilic and thus easily absorbed by the central and
peripheral nervous system tissues (Lock et al., 2013). There are
isolated cases of acute Parkinsonism associated with large solvent
exposures such as in workers exposed to n-hexane (Pezzoli et al.,
1989), and toluene (Papageorgiou et al., 2009), among others.
There is no consistent evidence of the association of solvent
exposure and PD (Wirdefeldt et al., 2011). One case-control
study based on a questionnaire reported an increased risk of
PD by the exposure to organic solvents (OR = 2.78, 95% CI,
1.23–6.26) in 86 PD patients and 86 controls from the Emilia-
Romagna region in Italy (Smargiassi et al., 1998). Another
case–control study reported an increased risk of PD when the
exposure to solvents was above 20 years (OR = 3.59, 95% CI,
1.26–19.26) in 182 cases (vs. 422 controls) identified through
death certificates of the Rolls-Royce PLC national pension fund
archive from employees of five manufacturing locations in
United Kingdom who had any mention of PD (McDonnell et al.,
2003).
Trichloroethylene (TCE) is one of the specific solvents that
has been investigated in detail (Goldman, 2014). Some clinical
case reports have reported the onset of PD in workers exposed
to TCE through chronic inhalation and dermal exposure by
handling TCE, suggesting a potential link between the exposure
to TCE and PD (Kochen et al., 2003; Gash et al., 2008). More
recently, an epidemiologic study in 99 twin pairs discordant for
PD showed that the exposure to TCEwas associated with a 6–fold
increased risk of PD (OR= 6.1, 95%CI, 1.2–33) (Goldman, 2014).
In animal models, TCE may recapitulate several key pathological
features of PD. The systemic exposure of adult rats to TCE
(1000 mg/Kg/day/5 days a week/2 and 6 weeks, oral gavage)
inhibits mitochondrial complex I enzyme activity, increases
oxidative stressmarkers, activates themicroglia, induces nigral α-
syn accumulation and a significant loss of dopaminergic neurons
on the SNpc in a dose-dependent manner, as well as defects in
the rotarod behavior test (Liu et al., 2010). In a similar way, the
administration of n-hexane and its metabolite 2, 5-hexanedione
(400 mg/Kg/day/5 days a week/6 weeks, i.p.) to mice caused
that both chemicals reduced the striatal dopamine concentration
by 38 and 33%, respectively, but neuronal cell loss was not
confirmed (Pezzoli et al., 1990). On the other hand, there is no
evidence that acute or subchronic exposure to toluene promotes
the degeneration of the nigrostriatal dopamine system (Lock
et al., 2013).
Nanoparticles and PD
Nanoparticles are an important alternative in the development of
treatment strategies for neurodegenerative diseases due to their
small particle size, large surface and high drug loading efficiency,
which allow them to cross the blood-brain barrier and efficiently
release specific drugs (Li et al., 2014b; Leyva-Gómez et al., 2015).
However, their small size allows them to penetrate the cell and
organelles, disrupting their normal function (Buzea et al., 2007).
Although some NPs are being used in therapies for PD,
no epidemiological studies are available associating them with
PD risk. However, there is evidence suggesting that they could
contribute to alter the molecular mechanisms involved in the
pathogenesis of PD. Thus, it was reported that intranasal
instillation of SiO2-NPs (20 µg/day/1–7 days) to rats resulted
in their presence in the striatum, the induction of oxidative
damage, an inflammatory response, and depleted dopamine
concentration and tyrosine hydroxylase levels, suggesting that
these NPs have a negative impact on striatal dopaminergic
neurons (Wu et al., 2011). Another report in adult zebrafish
exposed to SiO2-NPs (300 and 1000 µg/mL; 15 and 50-nm of
size) showed alterations in neurobehavioral parameters (general,
cognitive behavior and locomotive activity), with the most
significant effects observed with the smallest NPs, similar to
those observed in neurodegenerative diseases (Li et al., 2014b).
In vitro studies also support the potential contribution of NPs
in PD development. The exposure of dopaminergic neurons
(PC12 cells) to SiO2-NPs (25–200 µg/mL/24 h) triggered an
oxidative stress, disturbed the cell cycle, induced apoptosis, and
activated the p53-mediated signaling pathway (Wu et al., 2011);
while the exposure of these cells to TiO2-NPs (50, 100 and
200 mg/mL/24 h) induced a dose–dependent increase in the
expression and aggregation of α-syn, as well as a reduction
of the expressions of Parkin (E3 ligase), and the ubiquitin
C-terminal hydrolase (UCH-L1), these events were associated
with increased oxidative stress (Wu and Xie, 2014). Also,
the exposure PC12 cells to iron oxide (Fe2O3-NPs; 0.15–15
mM) decreased the neurite growth in response to the nerve
growth factor (NGF) (Pisanic et al., 2007). Likewise, citrate-
capped gold nanoparticles (Au-NPs; 0.3–32 nM, 10–22 nm)
produced a dose-dependent aggregation of purified α-syn,
being strongest for the smallest NPs (Alvarez et al., 2013).
In contrast, the administration of Neurotensin (NTS)-polyplex
NPs (8.5 nmol/Kg, i.v), a nanocarrier gene with a potential for
nanomedicine-based applications for PD treatment, to BALB/c
mice does not produce systemic inflammatory (up to 24 h
after treatment) nor hepatic cytotoxicity (at 24 and 96 h after
treatment), supporting the safety of these NTS-polyplex NPs as
a potential therapeutic approach (Hernandez et al., 2014).
Early Exposure to Environmental Factors and AD
or PD Development: Epigenetic Evidence
Epigenetic DNA modifications include DNA methylation,
histone post-translational modifications (mainly acetylation)
and miRNAs (Holliday, 2006). DNA methylation is one of
the most studied epigenetic modifications that influence the
gene expression. It involves the addition of methyl groups to
cytosine bases located at cytosine–phosphate–guanine (CpG)
sites by the action of DNA methyltransferases (DNMTs).
Alterations in DNA methylation on the promoter regions of
genes regulate the gene expression of important processes such as
embryonic development, cellular differentiation and aging (Bird,
2002). Increasing evidence suggests that epigenetic changes
in the developing embryo that may play important roles in
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the susceptibility to diseases in later life (imprinted disease
phenotypes) result from maternal exposures to environmental
stimuli at critical periods of development. This suggests that
a short exposure to chemicals could be memorized through
epigenetic mechanisms long after the chemical trigger has gone
(Jang and Serra, 2014), and recent studies have suggested that
an epigenetic component could be involved in neurodegenerative
diseases related to environmental factors (Marques et al., 2011).
The latent brain expression of genes observed in animals
developmentally exposed to an environmental contaminant may
be mediated through epigenetic pathways that are regulated
via the DNA methylation. While the conditions leading to
early life hypo- or hyper-methylation of specific genes are not
known, both can induce oxidative DNA damage; for instance
the hypo-methylation of APP gene increases its expression
driving the overproduction of APP and Aβ levels, which in
turn facilitate the ROS production damaging the DNA, and
producing neuronal loss. While the hyper-methylation affects
the gene transcription and DNA repair pathways. Therefore,
both changes in DNA methylation can impact gene expression
and imprint susceptibility to oxidative DNA damage in the
aged brain (Zawia et al., 2009). Thus, it is suggested that Pb
interferes with the DNA methylating capacity, thus altering the
expression of AD-related genes. The study performed in aged
monkeys developmentally exposed to Pb revealed a reduced
activity of brain Dnmt, and the exposure of mouse primary
cells from the cerebral cortex to Pb (0.1 µM) resulted in a
similar effect on Dnmt1 activity a week after 24 h-treatment
(Wu et al., 2008). Also, Bihaqi and Zawia (2012) showed a
significant latent increase in AD biomarkers an a reduction in the
protein and mRNA levels of DNA methylating enzymes Dnmt1
and Dnmt3a, and methyl CpG binding protein 2 (MeCP2) in
differentiated SH-SY5Y cells treated with Pb (5–100 µM/48 h)
and analyzed 6 days later (Bihaqi and Zawia, 2012). Aberrant
CpG methylation in APP, Tau and GSK3β genes was reported in
post-mortem brains (Iwata et al., 2014). In addition, it suggested
that reduced levels of CpG methylation in the promoter of
APP could be mediated by the oxidation of guanine (8-oxdG)
(Zawia et al., 2009); this is because the oxidation of guanine
in CpG dinucleotides inhibits adjacent cytosine methylation
(Weitzman et al., 1994). On the other hand, Cd, another metal
involved in AD pathology, reduces the enzymatic activity of
Dnmt in rat liver cell cultures (Poirier and Vlasova, 2002), but
this effect has not been evaluated in cerebral cells. While a
study showed that subchronic As exposure (3 and 36 ppm/from
gestation until 4 months of age) altered the methylation of genes
involved in neuronal plasticity, including reelin (RELN) and
protein phosphatase 1 (PP1), which was associated with memory
deficits (Martínez et al., 2011). Regarding other compounds, the
perinatal exposure to permethrin (34 mg/Kg/daily, by gavage
from postnatal day 6–21) to mice showed altered brain functions
including biomarkers of maintenance of dopaminergic neurons,
and impairment of spatial memory at 6 months of age (Nasuti
et al., 2013).
The relation between epigenetic modifications and PD has
been less studied; however, a potential role of DNA methylation
in the promoter of α-syn encoding gene (SNCA) in the
neuropathogenesis of PD has been suggested, considering that α-
syn is a fundamental component of LB, the main hallmark of PD
(Lu et al., 2013). A DNA hypomethylation of SNCA was reported
in the substantia nigra of sporadic PD patients, suggesting that
it might contribute to the dysregulation of SNCA expression in
PD (Jowaed et al., 2010; Matsumoto et al., 2010). In addition,
increased SNCA mRNA levels were observed in SNpc of PD
(Chiba-Falek et al., 2006), and reduced levels of Dnmt1 have
been observed in postmortem brains from PD and dementia
with LB (DLB) patients, as well as in brains of α-syn transgenic
mice; authors suggest that this effect could be a novel mechanism
of epigenetic dysregulation in LB-related diseases such as PD
(Desplats et al., 2011). Finally, a lesser degree of methyation
of the TNFα promoter, a key inflammatory cytokine associated
with dopaminergic cell death was observed in the SNpc from
PD patients, predisposing to an increase neuronal vulnerability
to inflammatory reactions (Mogi et al., 1996; Pieper et al., 2008).
Environmental factors associated with an increased risk of PD
such as pesticides can alter the expression of genes by epigenetic
mechanisms (Kwok, 2010). It was reported that pre-treatment
with 5-aza-2’deoxycytidine (5’-aza-dC, a DNMT inhibitor)
exacerbated the dopaminergic neuron damage induced by PQ,
MPP+, 6-hydroxydopamine (6-OHDA) and rotenone treatment,
and induced oxidative stress, the transcriptional up-regulation
of α-syn, and demethylation of the α-syn promoter (Wang
et al., 2013). Likewise, the folate deficiency sensitizes mice
to MPTP-induced PD-like pathology and motor dysfunction
(Duan et al., 2002); it is well known that folate deficiency alters
the development of human nervous system (Greenblatt et al.,
1994).
On the other hand, it was reported that the exposure to
environmental neurotoxicants associated with PD during early
life or pregnancy can determine the progressive damage of the
substantia nigra years before the onset of clinical parkinsonism,
as well as to increase the vulnerability to effects of a second
environmental factor (two–hit model) (Logroscino, 2005).
A study in C57BL/6 mice daily treated with pQ (0.3 mg/Kg)
or maneb (1 mg/Kg) or PQ + maneb from postnatal day 5–19
and then re-exposed as adults to PQ (10 mg/Kg) or maneb
(30 mg/Kg) or PQ + maneb (twice a week/3 weeks) showed
that dopaminergic cell loss and decreased dopamine levels were
amplified by the adult re-challenge to the pesticides, suggesting
that the developmental exposure to neurotoxins enhanced the
adult susceptibility to a new toxic insult (Thiruchelvam et al.,
2002). Similarly, prenatal exposure of pregnant C57BL/6J mice
to PQ (0.3 mg/Kg) or maneb (1 mg/Kg) altered the development
of the nigrostriatal system and enhanced its vulnerability to
neurotoxins later in life, which could contribute with the
development of PD during aging (Barlow et al., 2004).
Although there is no direct evidence linking early exposure to
environmental pollutants and epigenetic changes with increased
susceptibility to LOPD, there is a plausible association based on
the following considerations: (1) epigenetic alterations have been
observed in PD brains; (2) the exposure to environmental factors
is associated with an increased risk of LOPD development and
factors such as pesticides and metals can alter mechanisms of
epigenetic regulation such as DNA methylation; and (3) early
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exposure to environmental pollutants might be associated with
LOPD later in life. Further studies are needed to confirm this
hypothesis in this promising research field to understand the
mechanisms underlying the long-term effects of the environment
on the PD development.
Concluding Remarks
The emerging association between exposures to several toxic
compounds with neurodegenerative diseases is of considerable
public health importance, given the increasing dementia
prevalence, the negative social and economic consequences
of neurodegeneration-related disabilities, and the increasing
environmental pollution in some geographic areas worldwide.
Some of the epidemiological studies show not consistent results
on getting significant estimates of hazard risk for AD or PD,
mainly due to some limitations that include the difficulty
on accurate diagnosis for AD or PD cases due to the lack
of specific biomarkers, the deficiency to accurately assess
chronic exposures, and/or the lack of inclusion of important
confounding variables such as co-exposure to toxic compounds,
genetic variants and lifestyle among others. Nevertheless,
epidemiological studies along with experimental data have led
to highlight the potential risk to develop these degenerative
diseases due to the exposure to environmental pollutants such
as metals, NPs and pesticides, among others. Interestingly,
these pollutants show similar mechanisms of toxicity, which
converge in a generalized mechanism based on the generation
of oxidative stress that leads to common hallmarks of both
neurodegenerative disorders. For example, the generation of
oxidative stress by increasing the production of ROS and/or
deregulating the antioxidant enzymes promotes the formation
of protein aggregates such as Tau, Aβ or α-syn. This in
turn overwhelms the degradation systems, and produces the
activation of the glia inducing neuroinflammation, a process
that per se increases the generation of further oxidative stress
leading to a self-perpetuating cycle, and finally to neuronal loss
of specific brain region such as the hippocampus and cerebral
cortex in AD and substantia nigra in PD. The oxidative stress
induced by these neurotoxicants activates/inhibits signaling
pathways leading to augmented/diminished activity of enzymes
that promote the accumulation of toxic materials in neural
cells such as damaged/aberrant proteins, Aβ in AD or α–syn
in PD and oxidative byproducts, or the oxidation of DNA
that can alter genetic or epigenetic regulation. Furthermore,
the link between early life exposure to environmental factors
and the origin of neurodegenerative diseases is getting attention
and can help to clarify the role of the environment on
the development of these degenerative diseases. On the
other hand, the lack of specific/differential biomarkers for
AD or PD limits the early diagnosis and then the timely
treatment. In this regard, specific circulating miRNAs have
been associated with pathological processes such as AD and
PD, therefore they are promising non-invasive biomarkers for
these neurological diseases. Additionally, the identification of
biomarkers to determine the past exposure to environmental
pollutants is of vital importance for a better and opportune
management of these diseases. Thus, as we have more knowledge
of the risk from the exposure to environmental pollutants,
more well-designed epidemiological studies (controlling for
as many variables as possible and with high sample sizes)
are necessary to improve the quality of life of elderly and
to prevent the development of neurodegenerative diseases
worldwide.
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